A Prospective Randomized Study of Ramucircumab Plus Pembrolizumab Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
Protocol: SWOG – S2302 SCHEMA S2302 Please Note: Below is a brief list of eligibility, please contact Genesys Hurley Cancer Institute, Research Department at (810) 762-8181, (810) 762-8079 or (810) 792-8038 to discuss the complete list of eligibility. Thank you! Eligibility: Participants must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC) which is Stage […]
A Randomized Phase II Study of Capmatinib + Osimertinib with or without Ramucirumab in Participants with EGFR Mutant, MET Amplified Stage IV or Recurrent Non-Small Cell lung Cancer
Protocol : SWOG – S1900G SCHEMA S1900G Please Note: Below is only a partial list of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810) 762-8181, (810) 762-8079 or (810) 762-8038 to discuss the full list of eligibility. Thank you! Eligibility: Participants must have been assigned to S1900G by the SWOG Statistics […]
Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLS Patients with Exon 20 Insertion Mutations in EGFR
Protocol: ECOG – EA5162 SCHEMA EA5162 Please Note: Below is partial eligibility, for full eligibility requirements, please contact the Genesys Hurley Cancer Institute Research Department at (810)762-8181, (810)762-8079 and/or (810)762-8038. Thank you! Eligibility: Participants must have a pathologically-confirmed diagnosis of nonsmall cell lung cancer (NSCLC). Participants must have advanced disease – either stage IV disease, […]
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or without SBRT for PD-L1 Negative, Advanced Non-Small Cell Lung Cancer
Protocol: Alliance – A082002 SCHEMA A082002 Please Note: Below is partial eligibility, for full eligibility requirements, please contact the Genesys Hurley Cancer Institute Research Department at (810)762-8181, (810)762-8079 and/or (810)762-8038. Thank you! Eligibility: Histologic or cytologic diagnosis of Stage IV NSCLC using version AJCC 8th edition (includes M1a, M1b, and M1c stage disease). Patients with […]
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR Mutant Non Small Cell Lung Cancer
Protocol: ECOG – EA5182 SCHEMA EA5182 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Patient must have a pathologically-confirmed diagnosis of nonsquamous, non-small cell lung cancer. Patient must have advanced disease, defined as – either stage IV […]
Integration of Immunotherapy into Adjuvant Therapy for Resected Non Small Cell Lung Cancer: ALCHEMIST
Protocol: Alliance – A081801 SCHEMA A081801 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and (810) 762-8038. Thank you! Eligibility: Previously registered to A151216 Central and/or local testing of EGFR with no EGFR exon 19 deletion of EGFR L858 R mutation (applicable to […]
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab + SBRT Versus SBRT Alone in High Risk, Early Stage Non-Small Cell Lung Cancer
Protocol: SWOG – S1914 SCHEMA S1914 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Patient must have histologically or cytologically proven Stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC) without radiographic evidence of nodal or […]
A Phase II Study of Sotorasib in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer
Protocol: SWOG – S1900E SCHEMA S1900E Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Sub-Study of Lung Map Participants must have confirmed Stage IV or recurrent non-squamous non-small cell lung cancer (NSCLC). Mixed histology NSCLC with less […]
A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC
Protocol: ECOG – EA5191 SCHEMA EA9181 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Must be at least 18 years of age. Patient must have pathologically confirmed non-squamous non-small cell lung carcinoma (NSCLC). Patient must have […]
Randomized Phase III Trial of MED14736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Protocol: ECOG – EA5181 SCHEMA EA5181 Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! Eligibility: Must be at least 18 years of age. Patient must have one of the following: Newly diagnosed stage IIIA/B/C NSCLC (per the AJCC […]